Biocon Chief: Roche ‘Better Wake Up And Smell The Coffee’
This article was originally published in PharmAsia News
Executive Summary
Partners Biocon and Mylan have garnered about 26% market share between them for their biosimilar versions of trastuzumab in India, despite innovator Roche's alleged efforts to "fob off" competition.